{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T03:56:52Z","timestamp":1769140612694,"version":"3.49.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006683","name":"Xi\u2019an Jiaotong-Liverpool University","doi-asserted-by":"publisher","award":["RDF-22-02-013"],"award-info":[{"award-number":["RDF-22-02-013"]}],"id":[{"id":"10.13039\/501100006683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11095-025-03965-6","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:43:03Z","timestamp":1764088983000},"page":"2405-2427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis"],"prefix":"10.1007","volume":"42","author":[{"given":"Hanyan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1552-7529","authenticated-orcid":false,"given":"Yiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-2879","authenticated-orcid":false,"given":"Mingming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"3965_CR1","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1021\/acs.chemrev.1c00196","volume":"121","author":"D Willbold","year":"2021","unstructured":"Willbold D, Strodel B, Schr\u00f6der GF, et al. Amyloid-type protein aggregation and prion-like properties of amyloids. Chem Rev. 2021;121:8285\u2013307. https:\/\/doi.org\/10.1021\/acs.chemrev.1c00196.","journal-title":"Chem Rev"},{"key":"3965_CR2","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1016\/j.cell.2021.08.013","volume":"184","author":"MR Sawaya","year":"2021","unstructured":"Sawaya MR, Hughes MP, Rodriguez JA, et al. The expanding amyloid family: structure, stability, function, and pathogenesis. Cell. 2021;184:4857\u201373. https:\/\/doi.org\/10.1016\/j.cell.2021.08.013.","journal-title":"Cell"},{"key":"3965_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41583-022-00603-7","volume":"23","author":"D Li","year":"2022","unstructured":"Li D, Liu C. Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. Nat Rev Neurosci. 2022;23:523\u201334. https:\/\/doi.org\/10.1038\/s41583-022-00603-7.","journal-title":"Nat Rev Neurosci"},{"key":"3965_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3803\/EnM.2023.1621","volume":"38","author":"T Liu","year":"2023","unstructured":"Liu T, Li M, Cui C, et al. Association between serum amyloid A levels and type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrinol Metab. 2023;38:315\u201327. https:\/\/doi.org\/10.3803\/EnM.2023.1621.","journal-title":"Endocrinol Metab"},{"key":"3965_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","volume":"13","author":"SA Cuddy","year":"2020","unstructured":"Cuddy SA, Bravo PE, Falk RH, et al. Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease? Cardiovasc Imaging. 2020;13:1325\u201336. https:\/\/doi.org\/10.1016\/j.jcmg.2020.02.025.","journal-title":"Cardiovasc Imaging"},{"key":"3965_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176142","author":"V Golatkar","year":"2023","unstructured":"Golatkar V, Bhatt LK. Emerging therapeutic avenues in cardiac amyloidosis. Eur J Pharmacol. 2023. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176142.","journal-title":"Eur J Pharmacol"},{"key":"3965_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms23010025","volume":"23","author":"Y Saito","year":"2021","unstructured":"Saito Y, Nakamura K, Ito H. Molecular mechanisms of cardiac amyloidosis. Int J Mol Sci. 2021;23:25. https:\/\/doi.org\/10.3390\/ijms23010025.","journal-title":"Int J Mol Sci"},{"key":"3965_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2016.2839.","journal-title":"JAMA Cardiol"},{"key":"3965_CR9","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24:1677\u201396. https:\/\/doi.org\/10.1002\/ejhf.2589.","journal-title":"Eur J Heart Fail."},{"key":"3965_CR10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86:1036\u201343. https:\/\/doi.org\/10.1136\/jnnp-2014-308724.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3965_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","volume":"41","author":"L Chacko","year":"2020","unstructured":"Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41:1439\u201347. https:\/\/doi.org\/10.1093\/eurheartj\/ehz905.","journal-title":"Eur Heart J."},{"key":"3965_CR12","doi-asserted-by":"publisher","first-page":"1154594","DOI":"10.3389\/fcvm.2023.1154594","volume":"10","author":"D Tomasoni","year":"2023","unstructured":"Tomasoni D, Bonfioli GB, Aimo A, et al. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. Front Cardiovasc Med. 2023;10:1154594. https:\/\/doi.org\/10.3389\/fcvm.2023.1154594.","journal-title":"Front Cardiovasc Med."},{"key":"3965_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"A Aimo","year":"2022","unstructured":"Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022;19:655\u201367. https:\/\/doi.org\/10.1038\/s41569-022-00683-z.","journal-title":"Nat Rev Cardiol"},{"key":"3965_CR14","doi-asserted-by":"publisher","first-page":"28776","DOI":"10.1038\/s41598-025-11795-0","volume":"15","author":"T Wakayama","year":"2025","unstructured":"Wakayama T, Yokouchi S, Kayano H, et al. Shadowless amyloid imaging with quantitative birefringence contrast. Sci Rep. 2025;15:28776. https:\/\/doi.org\/10.1038\/s41598-025-11795-0.","journal-title":"Sci Rep."},{"key":"3965_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nbt.2019.05.003","volume":"52","author":"C Stumptner","year":"2019","unstructured":"Stumptner C, Pabst D, Loibner M, et al. The impact of crosslinking and non-crosslinking fixatives on antigen retrieval and immunohistochemistry. New Biotechnol. 2019;52:69\u201383. https:\/\/doi.org\/10.1016\/j.nbt.2019.05.003.","journal-title":"New Biotechnol."},{"key":"3965_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/13506129.2019.1688289","volume":"27","author":"N Abildgaard","year":"2020","unstructured":"Abildgaard N, Rojek AM, M\u00f8ller HEH, et al. Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits. Amyloid. 2020;27:59\u201366. https:\/\/doi.org\/10.1080\/13506129.2019.1688289.","journal-title":"Amyloid."},{"key":"3965_CR17","doi-asserted-by":"publisher","first-page":"107348","DOI":"10.1016\/j.carpath.2021.107348","volume":"53","author":"RJ Leguit","year":"2021","unstructured":"Leguit RJ, Vink A, de Jonge N, et al. Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis. Cardiovasc Pathol. 2021;53:107348. https:\/\/doi.org\/10.1016\/j.carpath.2021.107348.","journal-title":"Cardiovasc Pathol"},{"key":"3965_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/0004563213518758","volume":"51","author":"MV Bhole","year":"2014","unstructured":"Bhole MV, Sadler R, Ramasamy K. Serum-free light-chain assay: clinical utility and limitations. Ann Clin Biochem. 2014;51:528\u201342. https:\/\/doi.org\/10.1177\/0004563213518758.","journal-title":"Ann Clin Biochem"},{"key":"3965_CR19","doi-asserted-by":"publisher","first-page":"9547","DOI":"10.1073\/pnas.95.16.9547","volume":"95","author":"A Solomon","year":"1998","unstructured":"Solomon A, Weiss DT, Murphy CL, et al. Light chain-associated amyloid deposits comprised of a novel \u03ba constant domain. Proc Natl Acad Sci USA. 1998;95:9547\u201351. https:\/\/doi.org\/10.1073\/pnas.95.16.9547.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3965_CR20","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.3390\/molecules26123571","volume":"26","author":"GJ Morgan","year":"2021","unstructured":"Morgan GJ. Barriers to small molecule drug discovery for systemic amyloidosis. Molecules. 2021;26:3571. https:\/\/doi.org\/10.3390\/molecules26123571.","journal-title":"Molecules"},{"key":"3965_CR21","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1073\/pnas.82.10.3415","volume":"82","author":"B Frangione","year":"1985","unstructured":"Frangione B, Moloshok T, Prelli F, et al. Human lambda light-chain constant region gene CMor lambda: the primary structure of lambda VI Bence Jones protein Mor. Proc Natl Acad Sci USA. 1985;82:3415\u20139. https:\/\/doi.org\/10.1073\/pnas.82.10.3415.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3965_CR22","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1681\/ASN.V1271558","volume":"12","author":"PM Ronco","year":"2001","unstructured":"Ronco PM, Alyanakian MA, Mougenot B, et al. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol. 2001;12:1558\u201365. https:\/\/doi.org\/10.1681\/ASN.V1271558.","journal-title":"J Am Soc Nephrol"},{"key":"3965_CR23","doi-asserted-by":"publisher","first-page":"e52300","DOI":"10.7554\/eLife.52300","volume":"9","author":"P Kazman","year":"2020","unstructured":"Kazman P, Vielberg MT, Pulido Cendales MD, et al. Fatal amyloid formation in a patient\u2019s antibody light chain is caused by a single point mutation. Elife. 2020;9:e52300. https:\/\/doi.org\/10.7554\/eLife.52300.","journal-title":"Elife"},{"key":"3965_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jmb.2013.10.016","volume":"426","author":"LM Blancas-Mej\u00eda","year":"2014","unstructured":"Blancas-Mej\u00eda LM, Tischer A, Thompson JR, et al. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations. J Mol Biol. 2014;426:347\u201361. https:\/\/doi.org\/10.1016\/j.jmb.2013.10.016.","journal-title":"J Mol Biol"},{"key":"3965_CR25","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.3390\/ijms23116336","volume":"23","author":"H Ikura","year":"2022","unstructured":"Ikura H, Endo J, Kitakata H, et al. Molecular mechanism of pathogenesis and treatment strategies for AL amyloidosis. Int J Mol Sci. 2022;23:6336. https:\/\/doi.org\/10.3390\/ijms23116336.","journal-title":"Int J Mol Sci"},{"key":"3965_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ajh.21815","volume":"85","author":"MS Davids","year":"2010","unstructured":"Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol. 2010;85:787\u201390. https:\/\/doi.org\/10.1002\/ajh.21815.","journal-title":"Am J Hematol"},{"key":"3965_CR27","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"RA Kyle","year":"1992","unstructured":"Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817\u201322. https:\/\/doi.org\/10.1182\/blood.V79.7.1817.1817.","journal-title":"Blood."},{"key":"3965_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/13506129.2022.2127088","volume":"30","author":"F Noborn","year":"2022","unstructured":"Noborn F, Thomsen C, Vorontsov E, et al. Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies. Amyloid. 2022;30:96\u2013108. https:\/\/doi.org\/10.1080\/13506129.2022.2127088.","journal-title":"Amyloid"},{"key":"3965_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583\u201396. https:\/\/doi.org\/10.1056\/NEJMra023144.","journal-title":"N Engl J Med"},{"key":"3965_CR30","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.labinv.2022.100001","volume":"103","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yu W, Chang W, et al. Light chain amyloidosis-induced autophagy is mediated by the Foxo3a\/Beclin-1 pathway in cardiomyocytes. Lab Invest. 2023;103:100001. https:\/\/doi.org\/10.1016\/j.labinv.2022.100001.","journal-title":"Lab Invest"},{"key":"3965_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-021-00483-7","volume":"11","author":"M Hasib Sidiqi","year":"2021","unstructured":"Hasib Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J. 2021;11:90. https:\/\/doi.org\/10.1038\/s41408-021-00483-7.","journal-title":"Blood Cancer J"},{"key":"3965_CR32","doi-asserted-by":"publisher","first-page":"838","DOI":"10.7326\/0003-4819-131-11-199912070-00007","volume":"131","author":"JA Suwaidi","year":"1999","unstructured":"Suwaidi JA, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999;131:838\u201341. https:\/\/doi.org\/10.7326\/0003-4819-131-11-199912070-00007.","journal-title":"Ann Intern Med"},{"key":"3965_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12968-016-0240-7","volume":"18","author":"R Li","year":"2016","unstructured":"Li R, Yang ZG, Wen LY, et al. Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3T cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2016;18:16. https:\/\/doi.org\/10.1186\/s12968-016-0240-7.","journal-title":"J Cardiovasc Magn Reson"},{"key":"3965_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Bruyere J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358\u201367. https:\/\/doi.org\/10.1016\/j.jchf.2014.03.009.","journal-title":"JACC Heart Fail"},{"key":"3965_CR35","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1038\/s41467-021-26845-0","volume":"12","author":"P Kazman","year":"2021","unstructured":"Kazman P, Absmeier RM, Engelhardt H, Buchner J. Dissection of the amyloid formation pathway in AL amyloidosis. Nat Commun. 2021;12:6516. https:\/\/doi.org\/10.1038\/s41467-021-26845-0.","journal-title":"Nat Commun"},{"key":"3965_CR36","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41375-019-0640-4","volume":"34","author":"TL Jordan","year":"2020","unstructured":"Jordan TL, Maar K, Redhage KR, et al. Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia. 2020;34:1383\u201393. https:\/\/doi.org\/10.1038\/s41375-019-0640-4.","journal-title":"Leukemia"},{"key":"3965_CR37","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1096\/fj.15-272179","volume":"29","author":"F Lavatelli","year":"2015","unstructured":"Lavatelli F, Imperiini E, Orr\u00f9 S, et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB J. 2015;29:4614\u201328. https:\/\/doi.org\/10.1096\/fj.15-272179.","journal-title":"FASEB J"},{"key":"3965_CR38","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38\u03b1 MAPK pathway. Proc Natl Acad Sci USA. 2010;107:4188\u201393. https:\/\/doi.org\/10.1073\/pnas.0912263107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3965_CR39","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53:D1670\u20136. https:\/\/doi.org\/10.1093\/nar\/gkae973.","journal-title":"Nucleic Acids Res."},{"key":"3965_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med."},{"key":"3965_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"3965_CR42","doi-asserted-by":"publisher","first-page":"1558275","DOI":"10.3389\/fimmu.2025.1558275","volume":"16","author":"HT Morgan","year":"2025","unstructured":"Morgan HT, Derman BA, Ma H, et al. Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. Front Immunol. 2025;16:1558275. https:\/\/doi.org\/10.3389\/fimmu.2025.1558275.","journal-title":"Front Immunol"},{"key":"3965_CR43","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978\u201392. https:\/\/doi.org\/10.1200\/JCO.21.01992.","journal-title":"J Clin Oncol"},{"key":"3965_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4065\/mcp.2009.0547","volume":"85","author":"S Madan","year":"2010","unstructured":"Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010;85:232\u20138. https:\/\/doi.org\/10.4065\/mcp.2009.0547.","journal-title":"Mayo Clin Proc"},{"key":"3965_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers12010015","volume":"12","author":"F Bonello","year":"2019","unstructured":"Bonello F, Mina R, Boccadoro M, et al. Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma. Cancers (Basel). 2019;12:15. https:\/\/doi.org\/10.3390\/cancers12010015.","journal-title":"Cancers (Basel)"},{"key":"3965_CR46","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbmt.2018.11.016","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Alahdab F, Firwana B, et al. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine\/busulfan versus fludarabine\/melphalan: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25:728\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2018.11.016.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3965_CR47","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.bbmt.2019.01.009","volume":"25","author":"H Maymani","year":"2019","unstructured":"Maymani H, Lin P, Saliba RM, et al. Comparison of outcomes of allogeneic hematopoietic cell transplantation for multiple myeloma using three different conditioning regimens. Biol Blood Marrow Transplant. 2019;25:1039\u201344. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.009.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3965_CR48","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/j.clml.2019.09.503","volume":"19","author":"S Bal","year":"2019","unstructured":"Bal S, Sigler A, Chan A, et al. BCMA expression in AL amyloidosis. Clin Lymphoma Myeloma Leuk. 2019;19:e306. https:\/\/doi.org\/10.1016\/j.clml.2019.09.503.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3965_CR49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40265-022-01830-z","volume":"83","author":"G Palladini","year":"2023","unstructured":"Palladini G, Milani P. Diagnosis and treatment of AL amyloidosis. Drugs. 2023;83:203\u201316. https:\/\/doi.org\/10.1007\/s40265-022-01830-z.","journal-title":"Drugs"},{"key":"3965_CR50","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-22-0637","volume":"28","author":"S Kfir-Erenfeld","year":"2022","unstructured":"Kfir-Erenfeld S, Asherie N, Grisariu S, et al. Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Clin Cancer Res. 2022;28:5156\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0637.","journal-title":"Clin Cancer Res"},{"key":"3965_CR51","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1182\/blood.2020005278","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136:1632\u201344. https:\/\/doi.org\/10.1182\/blood.2020005278.","journal-title":"Blood."},{"key":"3965_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40364-023-00532-2","volume":"11","author":"F Korell","year":"2023","unstructured":"Korell F, Sch\u00f6nland S, Schmitt A, et al. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma. Biomark Res. 2023;11:91. https:\/\/doi.org\/10.1186\/s40364-023-00532-2.","journal-title":"Biomark Res"},{"key":"3965_CR53","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.32909","volume":"126","author":"H Einsele","year":"2020","unstructured":"Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126:3192\u2013201. https:\/\/doi.org\/10.1002\/cncr.32909.","journal-title":"Cancer"},{"key":"3965_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41408-023-00950-3","volume":"13","author":"R Chakraborty","year":"2023","unstructured":"Chakraborty R, Bhutani D, Maurer MS, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023;13:172. https:\/\/doi.org\/10.1038\/s41408-023-00950-3.","journal-title":"Blood Cancer J"},{"key":"3965_CR55","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/ejh.14348","volume":"114","author":"M Stalker","year":"2024","unstructured":"Stalker M, Garfall A, Cohen A, et al. Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis. Eur J Haematol. 2024;114:443\u20137. https:\/\/doi.org\/10.1111\/ejh.14348.","journal-title":"Eur J Haematol"},{"key":"3965_CR56","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"3965_CR57","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2024-200933","volume":"144","author":"PG Vianna","year":"2024","unstructured":"Vianna PG, Hossain S, Miller S, et al. Elranatamab in patients with daratumumab relapsed and\/or refractory light chain amyloidosis. Blood. 2024;144:3304. https:\/\/doi.org\/10.1182\/blood-2024-200933.","journal-title":"Blood"},{"key":"3965_CR58","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, et al. Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338. https:\/\/doi.org\/10.1182\/blood-2013-10-535088.","journal-title":"Blood"},{"key":"3965_CR59","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41408-022-00717-2","volume":"12","author":"J Khwaja","year":"2022","unstructured":"Khwaja J, Bomsztyk J, Mahmood S, et al. High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. Blood Cancer J. 2022;12:128. https:\/\/doi.org\/10.1038\/s41408-022-00717-2.","journal-title":"Blood Cancer J"},{"key":"3965_CR60","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/cells10030545","volume":"10","author":"G Palladini","year":"2021","unstructured":"Palladini G, Milani P, Malavasi F, Merlini G. Daratumumab in the treatment of light-chain (AL) amyloidosis. Cells. 2021;10:545. https:\/\/doi.org\/10.3390\/cells10030545.","journal-title":"Cells"},{"key":"3965_CR61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631.","journal-title":"N Engl J Med"},{"key":"3965_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-143180","volume":"136","author":"TL Parker","year":"2020","unstructured":"Parker TL, Rosenthal A, Sanchorawala V, et al. A phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated AL amyloidosis (SWOG S1702; NCT# 03499808). Blood. 2020;136:20\u20131. https:\/\/doi.org\/10.1182\/blood-2020-143180.","journal-title":"Blood"},{"key":"3965_CR63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5:417\u201321. https:\/\/doi.org\/10.1016\/s1535-6108(04)00120-5.","journal-title":"Cancer Cell"},{"key":"3965_CR64","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","volume":"129","author":"L Oliva","year":"2017","unstructured":"Oliva L, Orfanelli U, Resnati M, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017;129:2132\u201342. https:\/\/doi.org\/10.1182\/blood-2016-08-730978.","journal-title":"Blood"},{"key":"3965_CR65","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.7779.","journal-title":"J Clin Oncol"},{"key":"3965_CR66","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/DDDT.S93602","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz B, Ghazarian RN, Ou M, et al. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther. 2016;10:217\u201326. https:\/\/doi.org\/10.2147\/DDDT.S93602.","journal-title":"Drug Des Devel Ther."},{"key":"3965_CR67","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2020005086","volume":"130","author":"V Sanchorawala","year":"2017","unstructured":"Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597\u2013605. https:\/\/doi.org\/10.1182\/blood.2020005086.","journal-title":"Blood."},{"key":"3965_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","volume":"36","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Kastritis E, Wechalekar AD, et al. A randomized phase 3 study of ixazomib\u2013dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis. Leukemia. 2022;36:225\u201335. https:\/\/doi.org\/10.1038\/s41375-021-01317-y.","journal-title":"Leukemia"},{"key":"3965_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jconrel.2019.04.006","volume":"302","author":"JE Park","year":"2019","unstructured":"Park JE, Park J, Jun Y, et al. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. J Control Release. 2019;302:148\u201359. https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.006.","journal-title":"J Control Release"},{"key":"3965_CR70","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","volume":"128","author":"AD Cohen","year":"2016","unstructured":"Cohen AD, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2016;128:645. https:\/\/doi.org\/10.1182\/blood.V128.22.645.645.","journal-title":"Blood"},{"key":"3965_CR71","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1586\/14737140.7.7.945","volume":"7","author":"P Falco","year":"2007","unstructured":"Falco P, Bringhen S, Avonto I, et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther. 2007;7:945\u201357. https:\/\/doi.org\/10.1586\/14737140.7.7.945.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3965_CR72","doi-asserted-by":"publisher","first-page":"114494","DOI":"10.1016\/j.ejmech.2022.114494","volume":"238","author":"R Pahwa","year":"2022","unstructured":"Pahwa R, Chhabra J, Kumar R, Narang R. Melphalan: recent insights on synthetic, analytical and medicinal aspects. Eur J Med Chem. 2022;238:114494. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114494.","journal-title":"Eur J Med Chem"},{"key":"3965_CR73","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1080\/13506129.2016.1258356","volume":"23","author":"AJ Cowan","year":"2016","unstructured":"Cowan AJ, et al. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Amyloid. 2016;23:254\u20139. https:\/\/doi.org\/10.1080\/13506129.2016.1258356.","journal-title":"Amyloid"},{"key":"3965_CR74","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40265-021-01522-0","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Melphalan flufenamide (Melflufen): first approval. Drugs. 2021;81:963\u20139. https:\/\/doi.org\/10.1007\/s40265-021-01522-0.","journal-title":"Drugs"},{"key":"3965_CR75","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1703200","volume":"28","author":"V Sanchorawala","year":"2001","unstructured":"Sanchorawala V, Wright D, Seldin D, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637\u201342. https:\/\/doi.org\/10.1038\/sj.bmt.1703200.","journal-title":"Bone Marrow Transplant."},{"key":"3965_CR76","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85\u201393. https:\/\/doi.org\/10.7326\/0003-4819-140-2-200401200-00008.","journal-title":"Ann Intern Med"},{"key":"3965_CR77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0268-960x(92)90028-o","volume":"6","author":"A Hall","year":"1992","unstructured":"Hall A, Tilby M. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992;6:163\u201373. https:\/\/doi.org\/10.1016\/0268-960x(92)90028-o.","journal-title":"Blood Rev"},{"key":"3965_CR78","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119:4391\u20134. https:\/\/doi.org\/10.1182\/blood-2011-11-390930.","journal-title":"Blood."},{"key":"3965_CR79","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1182\/bloodadvances.2022007781","volume":"6","author":"E Muchtar","year":"2022","unstructured":"Muchtar E, Gertz MA, LaPlant BR, et al. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Adv. 2022;6:5429\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2022007781.","journal-title":"Blood Adv."},{"key":"3965_CR80","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","volume":"8","author":"J Villar","year":"2020","unstructured":"Villar J, Ferrando C, Mart\u00ednez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267\u201376. https:\/\/doi.org\/10.1016\/S2213-2600(19)30417-5.","journal-title":"Lancet Respir Med"},{"key":"3965_CR81","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","volume":"80","author":"R Alexanian","year":"1992","unstructured":"Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887\u201390. https:\/\/doi.org\/10.1182\/blood.V80.4.887.887.","journal-title":"Blood"},{"key":"3965_CR82","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38:3252\u201360. https:\/\/doi.org\/10.1200\/JCO.20.01285.","journal-title":"J Clin Oncol."},{"key":"3965_CR83","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.leukres.2012.05.010","volume":"36","author":"L Sedlarikova","year":"2012","unstructured":"Sedlarikova L, Kubiczkova L, Sevcikova S, et al. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. 2012;36:1218\u201324. https:\/\/doi.org\/10.1016\/j.leukres.2012.05.010.","journal-title":"Leuk Res"},{"key":"3965_CR84","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135. https:\/\/doi.org\/10.1126\/science.1244851.","journal-title":"Science"},{"key":"3965_CR85","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","volume":"105","author":"G Palladini","year":"2005","unstructured":"Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105:2949\u201351. https:\/\/doi.org\/10.1182\/blood-2004-08-3231.","journal-title":"Blood"},{"key":"3965_CR86","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","volume":"109","author":"AD Wechalekar","year":"2007","unstructured":"Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109:457\u201364. https:\/\/doi.org\/10.1182\/blood-2006-07-035352.","journal-title":"Blood"},{"key":"3965_CR87","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/bjh.12973","volume":"166","author":"S Mahmood","year":"2014","unstructured":"Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166:842\u20138. https:\/\/doi.org\/10.1111\/bjh.12973.","journal-title":"Br J Haematol"},{"key":"3965_CR88","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.critrevonc.2016.01.004","volume":"99","author":"T Jelinek","year":"2016","unstructured":"Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. 2016;99:249\u201360. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.004.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3965_CR89","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","volume":"119","author":"A Dispenzieri","year":"2012","unstructured":"Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119:5397\u2013404. https:\/\/doi.org\/10.1182\/blood-2012-02-413161.","journal-title":"Blood"},{"key":"3965_CR90","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/cancers15061710","volume":"15","author":"E Lebel","year":"2023","unstructured":"Lebel E, Kastritis E, Palladini G, et al. Venetoclax in relapse\/refractory AL amyloidosis\u2014a multicenter international retrospective real-world study. Cancers. 2023;15:1710. https:\/\/doi.org\/10.3390\/cancers15061710.","journal-title":"Cancers"},{"key":"3965_CR91","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","volume":"11","author":"VJ Premkumar","year":"2021","unstructured":"Premkumar VJ, Lentzsch S, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis. Blood Cancer J. 2021;11:10. https:\/\/doi.org\/10.1038\/s41408-020-00397-w.","journal-title":"Blood Cancer J"},{"key":"3965_CR92","doi-asserted-by":"publisher","unstructured":"Chen X, Wu X, Li L, Zhu X. Development of proteasome inhibitors for cancer therapy. Int J Drug Discov Pharmacol. 2024;100004. https:\/\/doi.org\/10.53941\/ijddp.2024.100004.","DOI":"10.53941\/ijddp.2024.100004"},{"key":"3965_CR93","doi-asserted-by":"publisher","unstructured":"Gomes SQ, Silva GM, Barcelos MP, et al. Structural aspects of organic compounds as proteasome inhibitors addressed to several diseases. In: Research Topics in Bioactivity, Environment and Energy: Experimental and Theoretical Tools. Springer; 2022. p.545\u2013567. https:\/\/doi.org\/10.1007\/978-3-031-07622-0_22.","DOI":"10.1007\/978-3-031-07622-0_22"},{"key":"3965_CR94","unstructured":"PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Bioassay Record for AID 1321018, Source: ChEMBL. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/1321018. Accessed 27 Sep t2024."},{"key":"3965_CR95","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1016\/j.bmcl.2010.04.086","volume":"20","author":"J Matharu","year":"2010","unstructured":"Matharu J, Oki J, Worthen DR, et al. Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood\u2013brain barrier. Bioorg Med Chem Lett. 2010;20:3688\u201391. https:\/\/doi.org\/10.1016\/j.bmcl.2010.04.086.","journal-title":"Bioorg Med Chem Lett"},{"key":"3965_CR96","unstructured":"PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Bioassay Record for AID 34176, Source: ChEMBL. Available from: \nhttps:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/34176. Accessed 27 Sep t2024."},{"key":"3965_CR97","unstructured":"PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Bioassay Record for AID 1462168, Displacement of (3H)-dexamethasone from glucocorticoid receptor (unknown origin) at 1 uM, Source: ChEMBL. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/1462168. Accessed 27 Sep t2024."},{"key":"3965_CR98","unstructured":"PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Bioassay Record for AID 492054, Selectivity index, ratio of Ki for bovine thrombin to human tryptase-beta, Source: ChEMBL. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/bioassay\/492054. Accessed 6 Mar\u00a02025."},{"key":"3965_CR99","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1021\/acsmedchemlett.0c00214","volume":"11","author":"RB Kargbo","year":"2020","unstructured":"Kargbo RB. Ligand design for cereblon-based immunomodulatory therapy. ACS Med Chem Lett. 2020;11:1088\u20139. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00214.","journal-title":"ACS Med Chem Lett"},{"key":"3965_CR100","doi-asserted-by":"publisher","first-page":"14513","DOI":"10.1021\/acs.jmedchem.3c00851","volume":"66","author":"C Steinebach","year":"2023","unstructured":"Steinebach C, Bricelj A, Murgai A, et al. Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs. J Med Chem. 2023;66:14513\u201343. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00851.","journal-title":"J Med Chem"},{"key":"3965_CR101","doi-asserted-by":"publisher","first-page":"128215","DOI":"10.1016\/j.bmcl.2021.128215","volume":"47","author":"Q Niu","year":"2021","unstructured":"Niu Q, Deng H, Zhang Z, et al. Design, synthesis and biological evaluation of dual Bcl-2\/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl) benzoic acid scaffold. Bioorg Med Chem Lett. 2021;47:128215. https:\/\/doi.org\/10.1016\/j.bmcl.2021.128215.","journal-title":"Bioorg Med Chem Lett."},{"key":"3965_CR102","doi-asserted-by":"publisher","first-page":"101207","DOI":"10.1016\/j.blre.2024.101207","volume":"66","author":"J Wang","year":"2024","unstructured":"Wang J, Li J, Zhong L. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis. Blood Rev. 2024;66:101207. https:\/\/doi.org\/10.1016\/j.blre.2024.101207.","journal-title":"Blood Rev"},{"key":"3965_CR103","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","volume":"23","author":"M Renz","year":"2016","unstructured":"Renz M, Torres R, Dolan PJ, et al. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis. Amyloid. 2016;23:168\u201377. https:\/\/doi.org\/10.1080\/13506129.2016.1205974.","journal-title":"Amyloid."},{"key":"3965_CR104","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.2023021311","volume":"142","author":"A Huart","year":"2023","unstructured":"Huart A. Birtamimab: a new amyloidosis treatment? Blood. 2023;142:1178\u201380. https:\/\/doi.org\/10.1182\/blood.2023021311.","journal-title":"Blood"},{"key":"3965_CR105","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","volume":"157","author":"R Hrncic","year":"2000","unstructured":"Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000;157:1239\u201346. https:\/\/doi.org\/10.1016\/S0002-9440(10)64639-1.","journal-title":"Am J Pathol"},{"key":"3965_CR106","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijcard.2020.07.016","volume":"321","author":"M Valero-Mu\u00f1oz","year":"2020","unstructured":"Valero-Mu\u00f1oz M, Wilson RM, Bret\u00f3n-Romero R, et al. Doxycycline decreases amyloidogenic light chain-induced autophagy in isolated primary cardiac myocytes. Int J Cardiol. 2020;321:133\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2020.07.016.","journal-title":"Int J Cardiol."},{"key":"3965_CR107","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","volume":"118","author":"JE Ward","year":"2011","unstructured":"Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011;118:6610\u20137. https:\/\/doi.org\/10.1182\/blood-2011-04-351643.","journal-title":"Blood"},{"key":"3965_CR108","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/13506129.2022.2155809","volume":"30","author":"N Abdallah","year":"2023","unstructured":"Abdallah N, Dispenzieri A, Muchtar E, et al. The impact of post-transplant doxycycline in AL amyloidosis\u2013updated results after long-term follow-up. Amyloid. 2023;30:261\u20137. https:\/\/doi.org\/10.1080\/13506129.2022.2155809.","journal-title":"Amyloid"},{"key":"3965_CR109","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1074\/jbc.M116.750323","volume":"292","author":"K Andrich","year":"2017","unstructured":"Andrich K, Hegenbart U, Kimmich C, et al. Aggregation of full-length immunoglobulin light chains from systemic light chain amyloidosis (AL) patients is remodeled by epigallocatechin-3-gallate. J Biol Chem. 2017;292:2328\u201344. https:\/\/doi.org\/10.1074\/jbc.M116.750323.","journal-title":"J Biol Chem"},{"key":"3965_CR110","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/hemato2040050","volume":"2","author":"U Hegenbart","year":"2021","unstructured":"Hegenbart U, Raab MS, Sch\u00f6nland SO, et al. Treatment in AL amyloidosis: moving towards individualized and clone-directed therapy. Hemato. 2021;2:739\u201347. https:\/\/doi.org\/10.3390\/hemato2040050.","journal-title":"Hemato."},{"key":"3965_CR111","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","volume":"27","author":"M Oerlemans","year":"2019","unstructured":"Oerlemans M, Rutten KHG, Minnema MC, et al. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019;27:525\u201336. https:\/\/doi.org\/10.1007\/s12471-019-1299-1.","journal-title":"Neth Heart J."},{"key":"3965_CR112","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaf248","author":"S Wang","year":"2025","unstructured":"Wang S, Liu C, Guo Y, et al. Predicting prognosis of light-chain cardiac amyloidosis by magnetic resonance imaging and deep learning. Eur Heart J Cardiovasc Imaging. 2025. https:\/\/doi.org\/10.1093\/ehjci\/jeaf248.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"3965_CR113","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Writing Committee, Kittleson MM, Ruberg FL, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient\u00a0With Cardiac Amyloidosis. J Am Coll Cardiol. 2023;81:1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022.","journal-title":"J Am Coll Cardiol"},{"key":"3965_CR114","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1021\/acschemneuro.9b00092","volume":"10","author":"M Xu","year":"2019","unstructured":"Xu M, Loa-Kum-Cheung W, Zhang H, et al. Identification of a new \u03b1-synuclein aggregation inhibitor via mass spectrometry based screening. ACS Chem Neurosci. 2019;10:2683\u201391. https:\/\/doi.org\/10.1021\/acschemneuro.9b00092.","journal-title":"ACS Chem Neurosci."},{"key":"3965_CR115","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nchem.2129","volume":"7","author":"LM Young","year":"2015","unstructured":"Young LM, Saunders JC, Mahood RA, et al. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat Chem. 2015;7:73\u201381. https:\/\/doi.org\/10.1038\/nchem.2129.","journal-title":"Nat Chem"},{"key":"3965_CR116","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cbpa.2017.12.013","volume":"42","author":"CE Eyers","year":"2018","unstructured":"Eyers CE, Vonderach M, Ferries S, et al. Understanding protein\u2013drug interactions using ion mobility\u2013mass spectrometry. Curr Opin Chem Biol. 2018;42:167\u201376. https:\/\/doi.org\/10.1016\/j.cbpa.2017.12.013.","journal-title":"Curr Opin Chem Biol."},{"key":"3965_CR117","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s43586-024-00318-2","volume":"4","author":"DS Roberts","year":"2024","unstructured":"Roberts DS, Loo JA, Tsybin YO, et al. Top-down proteomics. Nat Rev Methods Primers. 2024;4:38. https:\/\/doi.org\/10.1038\/s43586-024-00318-2.","journal-title":"Nat Rev Methods Primers"},{"key":"3965_CR118","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1021\/jasms.2c00253","volume":"34","author":"A Depraz Depland","year":"2023","unstructured":"Depraz Depland A, Stroganova I, Wootton CA, et al. Developments in trapped ion mobility mass spectrometry to probe the early stages of peptide aggregation. J Am Soc Mass Spectrom. 2023;34:193\u2013204. https:\/\/doi.org\/10.1021\/jasms.2c00253.","journal-title":"J Am Soc Mass Spectrom"},{"key":"3965_CR119","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ymeth.2015.05.017","volume":"95","author":"LM Young","year":"2016","unstructured":"Young LM, Saunders JC, Mahood RA, et al. ESI-IMS-MS: A method for rapid analysis of protein aggregation and its inhibition by small molecules. Methods. 2016;95:62\u20139. https:\/\/doi.org\/10.1016\/j.ymeth.2015.05.017.","journal-title":"Methods."},{"key":"3965_CR120","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bjh.18226","volume":"198","author":"HV Giles","year":"2022","unstructured":"Giles HV, Wechalekar A, Pratt G. The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: where are we now and which questions remain unanswered? Br J Haematol. 2022;198:641\u201353. https:\/\/doi.org\/10.1111\/bjh.18226.","journal-title":"Br J Haematol"},{"key":"3965_CR121","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-4939-2205-5_19","volume":"1258","author":"S Bronsoms","year":"2015","unstructured":"Bronsoms S, Trejo SA. Applications of mass spectrometry to the study of protein aggregation. Methods Mol Biol. 2015;1258:331\u201345. https:\/\/doi.org\/10.1007\/978-1-4939-2205-5_19.","journal-title":"Methods Mol Biol."},{"key":"3965_CR122","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/0929866526666181128124241","volume":"26","author":"SD Maleknia","year":"2019","unstructured":"Maleknia SD, Downard KM. Protein footprinting with radical probe mass spectrometry: two decades of achievement. Protein Peptide Lett. 2019;26:4\u201315. https:\/\/doi.org\/10.2174\/0929866526666181128124241.","journal-title":"Protein Peptide Lett"},{"key":"3965_CR123","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.3390\/jcm12124029","volume":"12","author":"MC Nackenhorst","year":"2023","unstructured":"Nackenhorst MC, Kapalla M, Weidle S, et al. The incidence of IgG4-related and inflammatory abdominal aortic aneurysm is rare in a 101 patient cohort. J Clin Med. 2023;12:4029. https:\/\/doi.org\/10.3390\/jcm12124029.","journal-title":"J Clin Med."},{"key":"3965_CR124","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf152","author":"J Qin","year":"2025","unstructured":"Qin J, Qiu Z, Fan Y, et al. In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls and potential. Cardiovasc Res. 2025. https:\/\/doi.org\/10.1093\/cvr\/cvaf152.","journal-title":"Cardiovasc Res"},{"key":"3965_CR125","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1038\/s41467-024-50224-0","volume":"15","author":"M Prondzynski","year":"2024","unstructured":"Prondzynski M, Berkson P, Trembley MA, et al. Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems. Nat Commun. 2024;15:5929. https:\/\/doi.org\/10.1038\/s41467-024-50224-0.","journal-title":"Nat Commun"},{"key":"3965_CR126","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/biomedicines11020334","volume":"11","author":"E Simons","year":"2023","unstructured":"Simons E, Loeys B, Alaerts M. iPSC-derived cardiomyocytes in inherited cardiac arrhythmias: pathomechanistic discovery and drug development. Biomedicines. 2023;11:334. https:\/\/doi.org\/10.3390\/biomedicines11020334.","journal-title":"Biomedicines"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03965-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:50:52Z","timestamp":1768927852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03965-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":126,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3965"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03965-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}